BioModels

The paper describes a submodel of oncolytic virotherapy. Created by COPASI 4.25 (Build 207) This model is described in the article: Memory versus effector immune responses in oncolytic virotherapies Cicely Macnamara, Raluca Eftimie Abstract: The main priority when designing cancer immuno-therapies has been to seek viable biological mechanisms that lead to permanent cancer eradica- tion or cancer control. Understanding the delicate balance between the role of effector and memory cells on eliminating cancer cells remains an elusive problem in immunology. Here we make an initial investigation into this problem with the help of a mathematical model for oncolytic virotherapy; although the model can in fact be made general enough to be applied also to other immunological problems. Our results show that long-term cancer con- trol is associated with a large number of persistent effector cells (irrespective of the initial peak in effector cell numbers). However, this large number of persistent effector cells is sustained by a relatively large number of memory cells. Moreover, we show that cancer control from a dormant state cannot be predicted by the size of the memory population. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

• Memory versus effector immune responses in oncolytic virotherapies.
• Macnamara C, Eftimie R
• Journal of theoretical biology , 7/ 2015 , Volume 377 , pages: 1-9 , PubMed ID: 25882747
Affiliation: Division of Mathematics, University of Dundee, Dundee DD1 4HN, United Kingdom. Electronic address: c.k.macnamara@dundee.ac.uk.
Abstract: The main priority when designing cancer immuno-therapies has been to seek viable biological mechanisms that lead to permanent cancer eradication or cancer control. Understanding the delicate balance between the role of effector and memory cells on eliminating cancer cells remains an elusive problem in immunology. Here we make an initial investigation into this problem with the help of a mathematical model for oncolytic virotherapy; although the model can in fact be made general enough to be applied also to other immunological problems. According to this model, we find that long-term cancer control is associated with a large number of persistent effector cells (irrespective of the initial peak in effector cell numbers). However, this large number of persistent effector cells is sustained by a relatively large number of memory cells. Moreover, the results of the mathematical model suggest that cancer control from a dormant state cannot be predicted by the size of the memory population.